The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The Prevention of Hospital Readmissions in Heart Failure
Open accessAbstract
Heart failure (HF) is a growing healthcare burden and one of the leading causes of hospitalizations and readmission. Preventing readmissions for HF patients is an increasing priority for clinicians, researchers, and various stakeholders. The following review will discuss the interventions found to reduce readmissions for patients and improve hospital performance on the 30-day readmission process measure. While evidence-based therapies for HF management have proliferated, the consistent implementation of these therapies and development of new strategies to more effectively prevent readmissions remain areas for continued improvement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure
Cleland, J. G. F., Daubert, J.-C., Erdmann, E., Freemantle, N., Gras, D., Kappenberger, L., & Tavazzi, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050496 · Cited by 6,276
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
Heart Disease and Stroke Statistics—2014 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2014) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,215
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111 · cited 1×
“eplerenone have both been shown in randomized clinical trials to reduce death and hospitalizations, with benefits seen within 30 days of initiation of therapy.(28,29) Recent observational data from discharge confirm that the addition of an aldosterone inhibitor reduces HF readmissions.”
BackgroundThe effect of digoxin on mortality and morbidity in patients with heart failure
(1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360801 · Cited by 3,016
Rich, M. W., Beckham, V., Wittenberg, C., Leven, C. L., Freedland, K. E., & Carney, R. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331806 · Cited by 2,328
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations
Boudoulas, K. D., Borer, J. S., & Boudoulas, H. (2015) · Cardiology · doi:10.1159/000435947 · Cited by 1,938
Cited by
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial
Lindenfeld, J., Zile, M. R., Desai, A. S., Bhatt, K., Ducharme, A., Horstmanshof, D., Krim, S. R., Maisel, A., Mehra, M. R., Paul, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01754-2 · Cited by 432
Frizzell, J. D., Liang, L., Schulte, P. J., Yancy, C. W., Heidenreich, P. A., Hernandez, A. F., Bhatt, D. L., Fonarow, G. C., & Laskey, W. K. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.3956 · Cited by 361
Self-citationRossignol, P., Hernandez, A. F., Solomon, S. D., & Zannad, F. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31808-7 · Cited by 316
Zangger, G., Bricca, A., Liaghat, B., Juhl, C. B., Mortensen, S. R., Andersen, R. M., Damsted, C., Hamborg, T. G., Ried-Larsen, M., Tang, L. H., et al. (2023) · Journal of Medical Internet Research · doi:10.2196/46439 · Cited by 116
Cunningham, J. W., Singh, P., Reeder, C., Claggett, B., Marti-Castellote, P. M., Lau, E. S., Khurshid, S., Batra, P., Lubitz, S. A., Maddah, M., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2023.4859 · Cited by 38
Metadata
- Authors
- Ziaeian, B., & Fonarow, G. C.
- Venue
- Progress in Cardiovascular Diseases
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 58
- Issue
- 4
- Pages
- 379-385
- ISSN
- 0033-0620 (ISSN-L)
- OpenAlex
- W1787714973
- Cited by
- 260
- References
- 52
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Prevention of Hospital Readmissions in Heart Failure. https://app.cochat.ai/papers/10.1016/j.pcad.2015.09.004
- The paper
- Ziaeian, B., & Fonarow, G. C. (2016). The Prevention of Hospital Readmissions in Heart Failure. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2015.09.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.